DSM Anti-Infectives, a $20 billion pharma firm based in the Netherlands, Wednesday said it would invest $500 million in India and hoped to capture a 10 percent share of the country's antibiotics market.
"We are continuously exploring opportunities to invest in India. Currently, our sales in India is $100 million per annum," said company president Gerard Reuver, launching a new penicillin-based antibiotic, Purimox, in the country.
"We plan to invest half a billion dollars in various other innovations," he said here at the opening of a new manufacturing plant to produce Purimox that is used to manufacture a variety of drugs.
The facility was inaugurated by the Netherlands Ambassador to India Eric F. CH. Niehe and Punjab's Minister for Technical Education R.C. Dogra.
N.V. Ramanna, vice president of the Dutch company, said the present size of the plant was 2,000 tonnes and would be expanded soon by another 3,000 tonnes. "We plan to achieve a market share of 10 percent in the antibiotic market this fiscal."
A company official said Purimox produces amoxicillin using an enzymatic route and does not use solvents, which leads to a product of higher purity.